Private Biobanks Spark Ethical Concerns

See allHide authors and affiliations

Science  08 Nov 2002:
Vol. 298, Issue 5596, pp. 1160
DOI: 10.1126/science.298.5596.1160

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


As countries and health care providers rush to create huge new databases linked to genetic data (see main text), an increasing number of companies in the United States are amassing large, entirely private, "biobanks" of DNA and tissue samples. The companies either use this material themselves or sell it to drug companies or academic researchers for studying diseases, say, or tailoring drugs to individuals.